Omvoh

Omvoh is a once-daily oral antibody for adults with moderately to severely active ulcerative colitis. It targets inflammatory pathways to reduce bowel inflammation and improve symptoms.

Molecule Details :

  • Molecule Name :

    Mirikizumab-Mrkz
  • Innovator :

    ELI LILLY
  • Approval Date :

    26-Oct-23
  • NCE-1 Date :

    26-Oct-27
  • Dosage Form :

    IV Infusion
  • Strength :

    300mg/15ml
  • Therapeutic Category :

    Antiulcer
  • Revenue ($M) :

    132

Year-wise Projected Sales ($M) :

  • 2025 :

    308
  • 2026 :

    555
  • 2027 :

    683
  • 2028 :

    809
  • 2029 :

    921
  • 2030 :

    1,020
  • 2031 :

    1,113
Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Choose Spring Bio Solution?

Supported 1000+ Clinical Trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO Services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions 


Login NCE Grid

Register NCE Grid

Are you sure want to logout from NCE Grid?